{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:42:52Z","timestamp":1787002972736,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Additional copies of chromosome 1 long arm (1q) are frequently found in multiple myeloma (MM) and predict high-risk disease. Available data suggest a different outcome and biology of patients with amplification (Amp1q, \u22654 copies of 1q) vs. gain (Gain1q, 3 copies of 1q) of 1q. We evaluated the impact of Amp1q\/Gain1q on the outcome of newly diagnosed MM patients enrolled in the FORTE trial (NCT02203643). Among 400 patients with available 1q data, 52 (13%) had Amp1q and 129 (32%) Gain1q. After a median follow-up of 62 months, median progression-free survival (PFS) was 21.2 months in the Amp1q group, 54.9 months in Gain1q, and not reached (NR) in Normal 1q. PFS was significantly hampered by the presence of Amp1q (HR 3.34 vs. Normal 1q,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001; HR 1.99 vs. Gain1q,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0008). Patients with Gain1q had also a significantly shorter PFS compared with Normal 1q (HR 1.68,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0031). Concomitant poor prognostic factors or the failure to achieve MRD negativity predicted a median PFS\u2009&lt;\u200912 months in Amp1q patients. Carfilzomib\u2013lenalidomide\u2013dexamethasone plus autologous stem cell transplantation treatment improved the adverse effect of Gain1q but not Amp1q. Transcriptomic data showed that additional 1q copies were associated with deregulation in apoptosis signaling, p38 MAPK signaling, and Myc-related genes.\n                  <\/jats:p>","DOI":"10.1038\/s41408-024-01075-x","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T04:02:17Z","timestamp":1717732937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells"],"prefix":"10.1038","volume":"14","author":[{"given":"Mattia","family":"D\u2019Agostino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Rota-Scalabrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-3127","authenticated-orcid":false,"given":"Angelo","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Arigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"De Sabbata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pietrantuono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0984-5080","authenticated-orcid":false,"given":"Anna","family":"Pascarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pescosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Olivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Garzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Galieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-753X","authenticated-orcid":false,"given":"Federico","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3686-3188","authenticated-orcid":false,"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Stefanoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele Adolfo","family":"Calogero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-5209","authenticated-orcid":false,"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-6594","authenticated-orcid":false,"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"1075_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-134538","volume":"136","author":"A Perrot","year":"2020","unstructured":"Perrot A, Lauwers-Cances V, Cazaubiel T, Facon T, Caillot D, Clement-Filliatre L, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood. 2020;136:39.","journal-title":"Blood"},{"key":"1075_CR2","doi-asserted-by":"crossref","unstructured":"Caro J, Al Hadidi S, Usmani SZ, Yee AJ, Raje N, Davies FE. How to treat high-risk myeloma at diagnosis and relapse. In: American Society of Clinical Oncology, editor. Educational book. Alexandria (USA); vol. 2021.","DOI":"10.1200\/EDBK_320105"},{"key":"1075_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Rajkumar SV. The multiple myelomas\u2014current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15:409\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"1075_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14:100\u201313.","journal-title":"Nat Rev Clin Oncol"},{"key":"1075_CR5","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1075_CR6","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","volume":"20","author":"R Fonseca","year":"2006","unstructured":"Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20:2034\u201340.","journal-title":"Leukemia"},{"key":"1075_CR7","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724\u201332.","journal-title":"Blood"},{"key":"1075_CR8","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","volume":"21","author":"G An","year":"2015","unstructured":"An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015;21:2148\u201356.","journal-title":"Clin Cancer Res"},{"key":"1075_CR9","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/ajh.25994","volume":"95","author":"M Locher","year":"2020","unstructured":"Locher M, Steurer M, Jukic E, Keller MA, Fresser F, Ruepp C, et al. The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. Am J Hematol. 2020;95:1562\u201371.","journal-title":"Am J Hematol"},{"key":"1075_CR10","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","volume":"30","author":"H Avet-Loiseau","year":"2012","unstructured":"Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, et al. Long-term analysis of the ifm 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30:1949\u201352.","journal-title":"J Clin Oncol"},{"key":"1075_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","volume":"16","author":"P Nemec","year":"2010","unstructured":"Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010;16:548\u201354.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1075_CR12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","volume":"58","author":"GL Shah","year":"2017","unstructured":"Shah GL, Landau H, Londono D, Devlin SM, Kosuri S, Lesokhin AM, et al. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk Lymphoma. 2017;58:1823\u201331.","journal-title":"Leuk Lymphoma"},{"key":"1075_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbmt.2019.12.726","volume":"26","author":"A Varma","year":"2020","unstructured":"Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, et al. Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis. Biol Blood Marrow Transplant. 2020;26:665\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1075_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0254-0","volume":"9","author":"TM Schmidt","year":"2019","unstructured":"Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9:94.","journal-title":"Blood Cancer J"},{"key":"1075_CR15","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4:3509\u201319.","journal-title":"Blood Adv"},{"key":"1075_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119:940\u20138.","journal-title":"Blood"},{"key":"1075_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00611-x","volume":"12","author":"NH Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12:1\u20139.","journal-title":"Blood Cancer J"},{"key":"1075_CR18","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"1075_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.18.00776","volume":"37","author":"A Perrot","year":"2019","unstructured":"Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37:1657\u201365.","journal-title":"J Clin Oncol"},{"key":"1075_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33:159\u201370.","journal-title":"Leukemia"},{"key":"1075_CR21","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","volume":"106","author":"N Weinhold","year":"2021","unstructured":"Weinhold N, Salwender HJ, Cairns DA, Raab MS, Waldron G, Blau IW, et al. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica. 2021;106:2754\u20138.","journal-title":"Haematologica"},{"key":"1075_CR22","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy","year":"2007","unstructured":"Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276\u201384.","journal-title":"Blood"},{"key":"1075_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-019-0226-4","volume":"9","author":"JR Sawyer","year":"2019","unstructured":"Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, et al. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood. Cancer J.2019;9:62. https:\/\/doi.org\/10.1038\/s41408-019-0226-4.","journal-title":"Cancer J."},{"key":"1075_CR24","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22:1705\u201320.","journal-title":"Lancet Oncol"},{"key":"1075_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-020-04384-w","volume":"100","author":"S Oliva","year":"2021","unstructured":"Oliva S, De Paoli L, Ruggeri M, Caltagirone S, Troia R, Oddolo D, et al. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS\/SMM to newly diagnosed and relapsed multiple myeloma. Ann Hematol. 2021;100:437\u201343.","journal-title":"Ann Hematol"},{"key":"1075_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269\u201377.","journal-title":"Leukemia"},{"key":"1075_CR27","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272\u20137.","journal-title":"Haematologica"},{"key":"1075_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938550","volume":"12","author":"X Liu","year":"2022","unstructured":"Liu X, Jia S, Chu Y, Tian B, Gao Y, Zhang C, et al. Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens. Front Oncol. 2022;12:938550.","journal-title":"Front Oncol"},{"key":"1075_CR29","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","volume":"26","author":"M D\u2019Agostino","year":"2020","unstructured":"D\u2019Agostino M, Zaccaria GM, Ziccheddu B, Rustad EH, Genuardi E, Capra A, et al. Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing. Clin Cancer Res. 2020;26:4832\u201341.","journal-title":"Clin Cancer Res"},{"key":"1075_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16434-y","volume":"11","author":"SM Foltz","year":"2020","unstructured":"Foltz SM, Gao Q, Yoon CJ, Sun H, Yao L, Li Y, et al. Evolution and structure of clinically relevant gene fusions in multiple myeloma. Nat Commun. 2020;11:2666.","journal-title":"Nat Commun"},{"key":"1075_CR31","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Mor\u00e8 S, Corradini P, et al. High Levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:3120\u201331.","journal-title":"J Clin Oncol"},{"key":"1075_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics."},{"key":"1075_CR33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128:959\u201370.","journal-title":"Blood"},{"key":"1075_CR34","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11:eaau7746. https:\/\/doi.org\/10.1126\/scitranslmed.aau7746.","journal-title":"Sci Transl Med"},{"key":"1075_CR35","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1182\/blood-2022-167113","volume":"140","author":"A Patel","year":"2022","unstructured":"Patel A, Smith AC, Masih-Khan E, Samuel P, Lajkosz K, Bhella S, et al. Chromosome 1q abnormalities are not an independent predictor of survival in multiple myeloma. Blood. 2022;140:4354\u20135.","journal-title":"Blood"},{"key":"1075_CR36","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO.21.01987","volume":"41","author":"R Lannes","year":"2023","unstructured":"Lannes R, Samur M, Perrot A, Mazzotti C, Divoux M, Cazaubiel T, et al. In multiple myeloma, high-risk secondary genetic events observed at relapse are present from diagnosis in tiny, undetectable subclonal populations. J Clin Oncol. 2023;41:1695\u2013702.","journal-title":"J Clin Oncol"},{"key":"1075_CR37","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S2152-2650(21)02126-1","volume":"21","author":"P Kapoor","year":"2021","unstructured":"Kapoor P, Schmidt T, Jacobus S, Wei Z, Fonseca R, Callander NS, et al. OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial. Clin Lymphoma Myeloma Leuk. 2021;21:S33\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1075_CR38","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-20-4366","volume":"27","author":"B Ziccheddu","year":"2021","unstructured":"Ziccheddu B, Da Vi\u00e0 MC, Lionetti M, Maeda A, Morlupi S, Dugo M, et al. Functional impact of genomic complexity on the transcriptome of multiple myeloma. Clin Cancer Res. 2021;27:6479\u201390.","journal-title":"Clin Cancer Res"},{"key":"1075_CR39","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell\u2014redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"1075_CR40","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196\u2013206.","journal-title":"N Engl J Med"},{"key":"1075_CR41","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S2152-2650(21)02084-X","volume":"21","author":"R Tiedemann","year":"2021","unstructured":"Tiedemann R, Mahdipour-Shirayeh A, Erdmann N, Tagoug I. OAB-010: Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers. Clin Lymphoma Myeloma Leuk. 2021;21:S7.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01075-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T04:02:24Z","timestamp":1717732944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01075-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01075-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MD has received honoraria for lectures for GlaxoSmithKline, Sanofi, and Janssen; has served on the advisory boards for GlaxoSmithKline, Sanofi, and Bristol Myers Squibb. AB has served on the advisory boards for Amgen, GlaxoSmithKline, Janssen, Pfizer. PG has served on the advisory boards for Takeda and Incyte. EZ recieved honoraria from Janssen, Bristol-Myers Squibb, Amgen, Takeda. BB has received honoraria from Amgen, Janssen, Novartis, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Jazz pharmaceuticals, Astrazeneca and Incyte; has served on the advisory boards for Amgen and Jazz pharmaceuticals. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and AbbVie; has served on the advisory boards for Janssen and GlaxoSmithKline; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol Myers Squibb, and Mundipharma. PM has received honoraria from Celgene, Janssen, Takeda, Bristol Myers Squibb, Amgen, Novartis, Gilead, Jazz, Sanofi, AbbVie, and GlaxoSmithKline; has served on the advisory boards for Celgene, Janssen, Takeda, Bristol Myers Squibb, Amgen, Jazz, Sanofi, AbbVie, and GlaxoSmithKline. FG has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, and GlaxoSmithKline; has served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, Roche, Adaptive Biotechnologies, Oncopeptides, bluebird bio, and Pfizer. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}